1 / 17

Current Therapy in Postmenopausal Women and its Effect on Osteoporosis

Current Therapy in Postmenopausal Women and its Effect on Osteoporosis. Jeannette Ortega April 26, 2001. Menopause. age of onset: 45-55 years menstrual cycle stops permanently production of female sex hormones drops. Osteoporosis. net excess of bone resorption loss of bone mass

van
Télécharger la présentation

Current Therapy in Postmenopausal Women and its Effect on Osteoporosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Therapy in Postmenopausal Women and its Effect on Osteoporosis Jeannette Ortega April 26, 2001

  2. Menopause • age of onset: 45-55 years • menstrual cycle stops permanently • production of female sex hormones drops

  3. Osteoporosis • net excess of bone resorption • loss of bone mass • change in bone architecture • closely related to menopause due to estrogen insufficiency

  4. Current Therapies for Menopause • Estrogen (estrogen replacement therapy) • Estrogen and Progesterone (hormone replacement therapy) • Biphosphonates • Calcitonin

  5. Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density Henry Bone et. al. The Journal of Clinical Endocrinology and Metabolism

  6. Rationale • The effect of combined therapy on bone density and safety concerns associated with its use.

  7. Subjects and Methods • 2 year study • 425 postmenopausal, osteoporotic women • 4 treatment regimens: • alendronate and conjugated equine estrogen (CEE) • CEE and placebo alendronate • alendronate and placebo CEE • placebo alendronate and placebo CEE

  8. Subject and Methods • Measurements • bone mass density (BMD) • biochemical markers of bone turnover • safety and tolerability • bone biopsy with histomorphometry

  9. Results • BMD

  10. Results

  11. Results

  12. Results

  13. Results • Biochemical markers of bone turnover

  14. Results

  15. Results • Safety and tolerability

  16. Results • Histomorphometry

  17. Conclusions • Favorable effects in BMD with combined therapy • Decrease in bone markers • Good tolerability • Normal mineralization, lamellar bone, and bone quality

More Related